Search Protocols under revision. Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, IndolentNHL, T-cell typeNHL, T-Cell Type, Adult T-Cell Leukemia or LymphomaNHL, T-Cell Type, Anaplastic Large CellNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Lymphoblastic LymphomaNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupALK+CD30+HIV-associatedICD10C83.3C83.5C84.4C84.5C84.6C84.7C86.1C86.2C86.5C91.5-MeSHLymphoma, Large-Cell, AnaplasticLymphoma, Primary Cutaneous Anaplastic Large CellLymphoma, T-CellLymphoma, T-Cell, PeripheralSequenceChemotherapyChemo-substanceAlectinibBrentuximab vedotinCarboplatinCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideGemcitabineIfosfamidePrednisoloneRituximabVincristineChemo-substanceAlectinibBrentuximab vedotinCarboplatinCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideGemcitabineIfosfamidePrednisoloneRituximabVincristineChemo-substanceAlectinibBrentuximab vedotinCarboplatinCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideGemcitabineIfosfamidePrednisoloneRituximabVincristineChemo-substanceAlectinibBrentuximab vedotinCarboplatinCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideGemcitabineIfosfamidePrednisoloneRituximabVincristineNo. Substances1345 RadiotherapySupportive therapySupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chlorideSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chlorideSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chlorideSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chlorideNo. Substances246810Protocol classificationTherapy classificationalternativecurrent standardIntensityhigh doseStandard doseTherapy indicationFirst lineRelapse therapySecond lineTherapy phaseseveral possibleTherapy intentioncurativecurative or palliativepalliativeRisksAlopeciaAnemia Hb below 8g/dlAstheniaCardiotoxicityConstipationDiarrheaDyspneaEdemaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheInfectionsMucositisNeuropathyNeutropeniaOral MucositisPruritusPyrexiaRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract InfectionVomiting only studiesPublicationAuthorCrump MFukano RHorwitz SLevine APfreundschuh MPro BVan de Wyngaert ZVelasquez WSDiseaseaggressives B-/T-NHL, Erstlinie, ECOG 0-3anaplastisches großzelliges T-Zell Lymphom, rezidiviert oder therapierefraktär, ECOG 0-1fortgeschrittenes wiederkehrendes NHLneudiagnostiziertes, HIV assoziiertes T-Zell Lymphom, Erstlinie, Karnofsky >50%peripheres T-Zell Lymphom, CD30+, Erstlinie, ECOG 0-2Rezidivierte oder refraktäre, aggressive Lymphome, 2. Linie vor ASCT, ECOG 0-3Rezidiviertes oder refraktäres diffus großzelliges anaplastisches Lymphom, Zweitlinie, ECOG 0-2rezidiviertes oder refraktäres peripheres T-Zell Lymphom, CD30+, ECOG 0-3OriginDepartment of Hematology, Section of Lymphoma , M.D. Anderson Hospital, Houston, TexasDepartment of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CADepartment of Pediatrics, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanFox Chase Cancer Center, Philadelphia, SGN-35 trialGerman High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)Hématologie clinique et thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, FranceMemorial Sloan Kettering Cancer Center, New York, ECHELON-2 study groupNHL-B1 trial, DSHNHLPrincess Margaret Cancer Centre, Ontario, CanadaProtocols in Revision 9 protocols foundAlectinib 300, T-cell Lymphoma (PID2404 V1.1)Brentuximab Vedotin 1.8, T-cell Lymphoma (PID1925 V1.0)BV-ICE - Brentuximab Vedotin 1.8 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, T-cell Lymphoma (PID2420 V1.0)CHOEP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Etoposide 100 / Vincristine 2 / Prednisolone 100, peripheral T-cell lymphoma (PID719 V1.0)CHOP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, peripheral T-cell lymphoma (PID821 V1.0)COMP - Cyclophosphamide 750 / Doxorubicin Liposomal 50 / Vincristine 2 / Prednisolone 100, T-cell Lymphoma (PID469 V1.0)Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma (PID1204 V1.0)DHAP - Dexamethasone 40 / Cisplatin 100 / Cytarabine 2000, T-cell lymphoma, under 70 years of age (PID71 V1.1)R-GDP - Rituximab 375 / Gemcitabine 1000 / Dexamethasone 40 / Cisplatin 75, diffuse large B-non-Hodgkin Lymphoma (PID605 V1.4)
